A separate cluster dedicated to the study of biotechnology, in particular, countering biological threats, will be created at the Presidential University of Information and Cybersecurity, Minister of Health of Ukraine Viktor Liashko said.
“A separate cluster at the President’s University will be devoted to biotechnology: biological threats, chronic non-infectious diseases, aging of the population, many pathogens that cause diseases in humans and animals. These are all the threats for which we must prepare,” he said at the All-Ukrainian Forum entitled “Ukraine 30. Education and Science” on Monday.
According to him, this cluster will include: School of Biotechnology, Center for Clinical Research, National Health Research Center, Higher School of Medicine, BSL-3 laboratory, School of Public Health, and Center for Safe Professional Development.
As reported, President of Ukraine Volodymyr Zelensky signed a decree on the creation of a presidential University, which will study information and cyber security, artificial intelligence, nanotechnology, aerospace, energy and biotechnology.
The decree has not been made public yet.
Biopharma pharmaceutical company is mulling the possibility of building fractionation plants in Latin America and Africa, co-owner of the company Kostiantyn Yefymenko has said.
“Our next project will be the construction of a blood fractionation plant on other continents. We are now considering Latin America and Africa,” he said during a discussion at the Kyiv International Economic Forum.
Yefymenko noted that currently Biopharma chooses “between Egypt and Nigeria.”
“We associate this with the political situation in both countries. Our next investment will be the expansion of the business of blood plasma fractionation and the construction of plasma centers in these countries,” he said.
Biopharma is a Ukrainian biotechnology company, the only plant in Eastern Europe that has modern technologies, and has been producing and developing medicines from donated plasma for almost 50 years.
The company is focused on providing Ukraine with medicines and supplies its products to more than 30 countries of the world on a contractual basis. In the autumn of 2019, Biopharma moved its production to a new scientific and production complex in Bila Tserkva.
The company is developing a network of its own plasma centers. Now they work in Sumy, Shostka, Konotop, Cherkasy, Dnipro and Kharkiv.
